CARMs can be customized for activity against specific antigens, including those common in patients with LMD such as HER2 (breast cancer, lung cancer), or mesothelin (lung cancer), allowing targeted therapy against a given pathology, and may have improved survival in the tumor microenvironment as compared to CAR T cells [86, 87]. This evidence concerns the gene MSLN and breast cancer.